{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T12:29:27Z","timestamp":1763728167553},"reference-count":91,"publisher":"Informa UK Limited","issue":"5","funder":[{"name":"The author(s) reported that there is no funding associated with the work featured in this article"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Gastroenterology & Hepatology"],"published-print":{"date-parts":[[2022,5,4]]},"DOI":"10.1080\/17474124.2022.2065258","type":"journal-article","created":{"date-parts":[[2022,4,11]],"date-time":"2022-04-11T08:30:07Z","timestamp":1649665807000},"page":"411-423","update-policy":"http:\/\/dx.doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["A critical review of ozanimod for the treatment of adults with moderately to severely active ulcerative colitis"],"prefix":"10.1080","volume":"16","author":[{"given":"Roni","family":"Aoun","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Northwestern University\u2013Feinberg School of Medicine, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Hanauer","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Northwestern University\u2013Feinberg School of Medicine, Chicago, Illinois, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2022,6,9]]},"reference":[{"issue":"1","key":"cit0001","doi-asserted-by":"crossref","first-page":"56-66","DOI":"10.1038\/s41575-020-00360-x","volume":"18","author":"Kaplan GG","year":"2021","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"key":"cit0002","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7019a2"},{"issue":"1","key":"cit0003","first-page":"1","volume":"6","author":"Taku K","year":"2020","journal-title":"Nature Reviews: Disease Primers"},{"key":"cit0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.06.016"},{"key":"cit0005","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2016.10.036"},{"key":"cit0006","doi-asserted-by":"publisher","DOI":"10.1159\/000496739"},{"key":"cit0007","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000000152"},{"key":"cit0008","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2020.01.006"},{"key":"cit0009","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.221127"},{"key":"cit0010","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa050516"},{"key":"cit0011","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.05.048"},{"key":"cit0012","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.10.032"},{"key":"cit0013","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X17750355"},{"key":"cit0014","doi-asserted-by":"publisher","DOI":"10.1177\/1756284818821266"},{"key":"cit0015","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2017.02.005"},{"key":"cit0016","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2013.10.052"},{"key":"cit0017","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000001049"},{"key":"cit0018","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.138"},{"key":"cit0019","doi-asserted-by":"publisher","DOI":"10.2147\/CEG.S237646"},{"issue":"12","key":"cit0020","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/ecco-jcc\/jjw092","volume":"10","author":"Wyant T","year":"2016","journal-title":"J Crohn\u2019s Colitis"},{"key":"cit0021","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215734"},{"key":"cit0022","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-311079"},{"key":"cit0023","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2015.08.044"},{"key":"cit0024","unstructured":"National Library of Medicine (U.S.). Phase iii study of ajm300 in patients with active ulcerative colitis. Identifier NCT03531892.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03531892"},{"key":"cit0025","doi-asserted-by":"publisher","DOI":"10.1172\/JCI21404"},{"key":"cit0026","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900750"},{"key":"cit0027","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.01.043"},{"key":"cit0028","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.11.059"},{"issue":"1","key":"cit0029","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/ecco-jcc\/jjx117","volume":"12","author":"Hindryckx P","year":"2018","journal-title":"J Crohn\u2019s Colitis"},{"key":"cit0030","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.08.043"},{"key":"cit0031","unstructured":"National Library of Medicine (U.S.). a phase 3, multicenter, randomized, double-blind, parallel, placebo-controlled induction study of mirikizumab in conventional-failed and biologic-failed patients with moderately to severely active ulcerative colitis (LUCENT 1). Identifier NCT03518086. https:\/\/clinicaltrials.gov\/ct2\/show\/record\/NCT03518086?term=mirikizumab&cond=ulcerative+colitis&draw=2&rank=3"},{"journal-title":"United European Gastroenterology Week Virtual","year":"2021","author":"Ferrante M","key":"cit0032"},{"issue":"1","key":"cit0033","doi-asserted-by":"crossref","first-page":"S026","DOI":"10.1093\/ecco-jcc\/jjab075.025","volume":"15","author":"Schreiber S","year":"2021","journal-title":"J Crohn\u2019s Colitis"},{"key":"cit0034","unstructured":"National Library of Medicine (U.S.). A multicenter, randomized, double-blind, placebo controlled induction study to evaluate the efficacy and safety of risankizumab in subjects with moderately to severely active ulcerative colitis. Identifier NCT03398148. https:\/\/www.clinicaltrials.gov\/ct2\/show\/study\/NCT03398148?term=risankizumab&cond=ulcerative+colitis&draw=2&rank=1"},{"key":"cit0035","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2018.07.003"},{"key":"cit0036","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606910"},{"key":"cit0037","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2018.07.009"},{"key":"cit0038","unstructured":"National Library of Medicine (U.S.). Phase 3b\/4 randomized safety endpoint study of 2 doses of tofacitinib in comparison to a tumor necrosis factor (tnf) inhibitor in subjects with rheumatoid arthritis. Identifier NCT02092467. https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02092467"},{"key":"cit0039","unstructured":"U.S. Food & Drug Administration. 2021https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death"},{"issue":"10292","key":"cit0040","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/S0140-6736(21)00666-8","author":"Feagan BG","year":"2021","journal-title":"Lancet"},{"journal-title":"United European Gastroenterology Week Virtual","year":"2021","author":"Panaccione R","key":"cit0041"},{"key":"cit0042","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1905725"},{"key":"cit0043","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.01.008"},{"key":"cit0044","first-page":"1","author":"Jairath V","year":"2021","journal-title":"Expert Rev Gastroenterol Hepatol"},{"issue":"1","key":"cit0045","doi-asserted-by":"crossref","first-page":"S103","DOI":"10.1093\/ecco-jcc\/jjab073.108","volume":"15","author":"Eaton K","year":"2021","journal-title":"J Crohn\u2019s Colitis"},{"journal-title":"Inflamm Bowel Dis","year":"2021","author":"Noor NM","key":"cit0046"},{"key":"cit0047","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izz104"},{"issue":"9","key":"cit0048","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1093\/ecco-jcc\/jjab029","volume":"15","author":"Zhao M","year":"2021","journal-title":"J Crohn\u2019s Colitis"},{"key":"cit0049","doi-asserted-by":"publisher","DOI":"10.3390\/molecules22030344"},{"key":"cit0050","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2017.02.002"},{"key":"cit0051","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-6143.2004.00476.x"},{"key":"cit0052","doi-asserted-by":"publisher","DOI":"10.1038\/mi.2016.35"},{"key":"cit0053","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2016.00167"},{"key":"cit0054","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.03.007"},{"key":"cit0055","doi-asserted-by":"publisher","DOI":"10.1096\/fj.10-179028"},{"key":"cit0056","first-page":"1","author":"Rosen H","year":"2014","journal-title":"Sphingosine-1-Phosphate Signaling in Immunology and Infectious Diseases"},{"key":"cit0057","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.887"},{"key":"cit0058","doi-asserted-by":"publisher","DOI":"10.1124\/mol.115.100222"},{"key":"cit0059","doi-asserted-by":"publisher","DOI":"10.1007\/s40263-015-0261-z"},{"key":"cit0060","doi-asserted-by":"publisher","DOI":"10.1111\/bph.13476"},{"key":"cit0061","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0909494"},{"key":"cit0062","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)30475-6"},{"key":"cit0063","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(16)00018-1"},{"key":"cit0064","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30238-8"},{"key":"cit0065","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(19)30239-X"},{"issue":"5","key":"cit0066","first-page":"469","volume":"4","author":"Suh JH","year":"2015","journal-title":"Transl Cancer Res"},{"key":"cit0067","doi-asserted-by":"publisher","DOI":"10.1111\/nure.12014"},{"key":"cit0068","unstructured":"National Center for Biotechnology Information (2021). PubChem Compound Summary for CID 52938427, Ozanimod. 2021 Oct 3. https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Ozanimod."},{"key":"cit0069","unstructured":"National Library of Medicine (U.S.). a randomized trial on efficacy and safety of ozanimod for the treatment of covid-19 patients requiring oxygen support - a pilot trial. Identifier NCT04405102.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04405102"},{"key":"cit0070","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513248"},{"key":"cit0071","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8070227"},{"key":"cit0072","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S240861"},{"key":"cit0073","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.120.000220"},{"volume-title":"ZEPOSIA (Ozanimod) (Package Insert)","year":"2021","key":"cit0074"},{"journal-title":"Mult Scler J","year":"2021","author":"Naismith R","key":"cit0075"},{"key":"cit0076","doi-asserted-by":"publisher","DOI":"10.1136\/gut.47.3.404"},{"journal-title":"J Crohn\u2019s Colitis","year":"2021","author":"Sandborn WJ","key":"cit0077"},{"key":"cit0078","first-page":"S6","volume":"115","author":"Sandborn W","year":"2020","journal-title":"Official Journal of the American College of Gastroenterology| ACG"},{"key":"cit0079","volume":"115","author":"Danese S","year":"2020","journal-title":"Official Journal of the American College of Gastroenterology| ACG"},{"key":"cit0080","unstructured":"National Library of Medicine (U.S.). A phase 3, multicenter, open-label extension trial of oral rpc1063 as therapy for moderate to severe ulcerative colitis. Identifier NCT02531126. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02531126?term=ozanimod&cond=ulcerative+colitis&draw=2&rank=2"},{"volume-title":"ACG annual scientific meeting","author":"Dubinski M","key":"cit0081"},{"key":"cit0082","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.383"},{"key":"cit0083","doi-asserted-by":"publisher","DOI":"10.1007\/s13760-017-0794-7"},{"key":"cit0084","unstructured":"National Library of Medicine (U.S.). A multicenter, randomized, double-blind, parallel-group study to assess the efficacy and safety of oral etrasimod as induction and maintenance therapy for moderately to severely active crohn\u2019s disease. Identifier NCT04173273. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04173273"},{"key":"cit0085","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.96.15_supplement.2432","volume-title":"Pregnancy outcomes in the ozanimod multiple sclerosis clinical development program (2432)","author":"Minton N","year":"2021"},{"key":"cit0086","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.10.035"},{"key":"cit0087","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab016"},{"key":"cit0088","unstructured":"U.S. Food & Drug Administration. 2020. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2020\/209899Orig1s000ltr.pdf"},{"key":"cit0089","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(20)30188-6"},{"key":"cit0090","unstructured":"U.S. Food & Drug Administration. 2021. [cited 2021 Oct 11]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2021\/209899Orig1s001ltr.pdf"},{"key":"cit0091","unstructured":"Bristol Myers Squibb. 2021. [cited 2021 Oct 11]. Available from: https:\/\/news.bms.com\/news\/corporate-financial\/2021\/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-for-Zeposia-ozanimod-as-a-Treatment-for-Adult-Patients-with-Moderately-to-Severely-Active-Ulcerative-Colitis\/default.aspx"}],"container-title":["Expert Review of Gastroenterology & Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17474124.2022.2065258","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,21]],"date-time":"2024-09-21T22:43:20Z","timestamp":1726958600000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17474124.2022.2065258"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,4]]},"references-count":91,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5,4]]}},"alternative-id":["10.1080\/17474124.2022.2065258"],"URL":"https:\/\/doi.org\/10.1080\/17474124.2022.2065258","relation":{},"ISSN":["1747-4124","1747-4132"],"issn-type":[{"type":"print","value":"1747-4124"},{"type":"electronic","value":"1747-4132"}],"subject":[],"published":{"date-parts":[[2022,5,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierh20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierh20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2021-11-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-08","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}